Physician profile
Kyle Stuart Mancuso
NPI 1861175820
$2,046.30
in general payments reported to CMS, 2019-2025
20 companies · $971 in 2025
The $971 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $910 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.87 | 2023-2025 | |
| Novo Nordisk INC | $312.85 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $253.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $209.60 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $200.86 | 2024-2025 | |
| Glaxosmithkline, LLC. | $101.12 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $97.81 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $65.68 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $60.00 | 2025 | Freestyle Libre 3 |
| Corium, LLC | $45.84 | 2024-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $38.53 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.06 | 2024-2025 | Jardiance |
| Lundbeck LLC | $30.87 | 2024 | Rexulti |
| Exact Sciences Corporation | $28.70 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $26.63 | 2024 | Evenity, Prolia, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.77 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.71 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $19.34 | 2024 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $16.66 | 2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.14 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Mancuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.